Cardiovascular benefit of SGLT2 inhibitors

References

• Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015;24(5):463–469.
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; Jun75(12):1272–1277.
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10–8.
   PubMed Web of Science ®Google Scholar
• Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol. 2010; May6(5):307–311.
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011; Jan22(1):104–112.
   PubMed Web of Science ®Google Scholar
• Sabino-Silva R, Freitas HS, Lamers ML, et al. Na+-glucose cotransporter SGLT1 protein in salivary glands: potential involvement in the diabetes-induced decrease in salivary flow. J Membrane Biol. 2009; Mar228(2):63–69.
   PubMed Web of Science ®Google Scholar
• Zhou L, Cryan EV, D'Andrea MR, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339–346.
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA, et al. Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology. 2004;19:370–376.
   PubMed Web of Science ®Google Scholar
• Turk E, Martin MG, Wright EM. Structure of the human Na+/glucose cotransporter gene SGLT1. J Biol Chem. 1994;269(21):15204–15209.
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–38.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Brosius FC, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis. 2021;77(1):94–109.
   PubMed Web of Science ®Google Scholar
• Bishop JH, Elegbe R, Green R, et al. Effects of phlorizin on glucose, water and sodium handling by the rat kidney. J Physiol. 1978;275:467–480.
   PubMed Web of Science ®Google Scholar
• Tsujihara K, Hongu M, Saito K, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo). 1996;44(6):1174–1180.
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794–1800.
   PubMed Web of Science ®Google Scholar
• US-Food-and-Drug-Administration. FDA approves Invokana to treat type 2 diabetes: first in a new class of diabetes drugs. Press release. 2013.
   Google Scholar
• Kaul S, Bolger AF, Herrington D, et al.; American College of Cardiology Foundation. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the american heart association and american college of cardiology foundation. J Am Coll Cardiol. 2010;55(17):1885–1894.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Morrow DA, Mosenzon O, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021;23(6):1026–1036.
   PubMed Web of Science ®Google Scholar
• Packer M, Januzzi JL, Ferreira JP, et al.; for the EMPEROR‐Reduced Trial Committees and Investigators. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. Eur J Heart Fail. 2021;23(9):1529–1538.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Jr., Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704–712.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and Meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and Meta-analysis. JAHA. 2020;9(3):e014908.
   Google Scholar
• Zou CY, Liu XK, Sang YQ, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a Meta-analysis. Medicine (Baltimore. 2019;98(49):e18245.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network Meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.
   PubMedGoogle Scholar
• Maddox TM, Januzzi JL, Allen LA, Jr., et al.; Writing Committee. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(6):772–810.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596–e646.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD). Dia Care. 2020;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72(24):3200–3223.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021;373:n1091.
   PubMedGoogle Scholar
• Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial. Circulation. 2020;141(2):90–99.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al.; For the EMPEROR-Reduced Trial Committees and Investigators. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326–336.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a Meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829.
   PubMed Web of Science ®Google Scholar
• Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41(25):2379–2392.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(6):671–680.
   PubMed Web of Science ®Google Scholar
• FDA. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. U.S. Food and Drug Administration. Drug Safety and Availability. 2018. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes
   Google Scholar
• McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019;124 Suppl 1(Suppl 1):S45–S52.
   PubMedGoogle Scholar
• Avogaro A, Vigili de Kreutzenberg S, Negut C, et al. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol. 2004;93(8A):13A–16A.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–790.
   PubMed Web of Science ®Google Scholar
• Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112(7):1049–1057.
   PubMed Web of Science ®Google Scholar
• Farhangkhoee H, Khan ZA, Mukherjee S, et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol. 2003;35(12):1439–1448.
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H, Razeghi P. Heart disease in diabetes-resist the beginnings. J Am Coll Cardiol. 2004;43(2):315.
   PubMed Web of Science ®Google Scholar
• Packer M. Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 Diabetes. Diabetes Care. 2018;41(1):11–13.
   PubMed Web of Science ®Google Scholar
• Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528–2536.
   PubMed Web of Science ®Google Scholar
• Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479–487.
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Sjostrom CD, Greasley PJ, et al. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(12):2667–2673.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Jr., Xu J, Li J, et al. Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: Implications for cardiovascular risk reduction. j Am Coll Cardiol. 2020;76(18):2076–2085.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463–1476.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–1122.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195.
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019;73(15):1931–1944.
   PubMed Web of Science ®Google Scholar
• Abdurrachim D, Teo XQ, Woo CC, et al. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized 13 C magnetic resonance spectroscopy study. Diabetes Obes Metab. 2019;21(2):357–365.
   PubMed Web of Science ®Google Scholar
• Baker HE, Kiel AM, Luebbe ST, et al. Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol. 2019;114(3):25.
   PubMed Web of Science ®Google Scholar
• Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci. 2018;3(5):575–587.
   PubMedGoogle Scholar
• Maruyama T, Takashima H, Oguma H, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther. 2019;21(12):713–720.
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(Suppl 3):13–19.
   PubMedGoogle Scholar
• Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422–434.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–363.
   PubMed Web of Science ®Google Scholar
• Baranova O, Miranda LF, Pichiule P, et al. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci. 2007;27(23):6320–6332.
   PubMed Web of Science ®Google Scholar
• Adluri RS, Thirunavukkarasu M, Dunna NR, et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice. Antioxid Redox Signal. 2011;15(7):1789–1797.
   PubMed Web of Science ®Google Scholar
• Guo JY, Yang T, Sun XG, et al. Ischemic postconditioning attenuates liver warm ischemia-reperfusion injury through akt-eNOS-NO-HIF pathway. J Biomed Sci. 2011;18(1):79.
   PubMedGoogle Scholar
• Weidemann A, Bernhardt WM, Klanke B, et al. HIF activation protects from acute kidney injury. J Am Soc Nephrol. 2008;19(3):486–494.
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–197.
   PubMed Web of Science ®Google Scholar
• Zhdanov AV, Dmitriev RI, Golubeva AV, et al. Chronic hypoxia leads to a glycolytic phenotype and suppressed HIF-2 signaling in PC12 cells. Biochim Biophys Acta. 2013;1830(6):3553–3569.
   PubMed Web of Science ®Google Scholar
• Zhdanov AV, Waters AH, Golubeva AV, et al. Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. Exp Cell Res. 2015;330(1):13–28.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan SK, Shah YM. A Central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis . Nutr Healthy Aging. 2017;4(3):207–216.
   PubMedGoogle Scholar
• Wei H, Bedja D, Koitabashi N, et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling. Proc Natl Acad Sci USA. 2012;109(14):E841–50.
   PubMed Web of Science ®Google Scholar
• Krishnan J, Suter M, Windak R, et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009;9(6):512–524.
   PubMed Web of Science ®Google Scholar
• Albrecht M, Zitta K, Bein B, et al. Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. Basic Res Cardiol. 2013;108(1):314.
   PubMed Web of Science ®Google Scholar
• Choe SS, Shin KC, Ka S, et al. Macrophage HIF-2α ameliorates adipose tissue inflammation and insulin resistance in obesity. Diabetes. 2014;63(10):3359–3371.
   PubMed Web of Science ®Google Scholar
• Luo G, Jian Z, Zhu Y, et al. Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress. Int J Mol Med. 2019;43(5):2033–2043.
   PubMed Web of Science ®Google Scholar
• Qiu R, Li W, Liu Y. MicroRNA-204 protects H9C2 cells against hypoxia/reoxygenation-induced injury through regulating SIRT1-mediated autophagy. Biomed Pharmacother. 2018;100:15–19.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu D, Hu H, et al. HIF-1α/BNIP3 signaling pathway-induced-autophagy plays protective role during myocardial ischemia-reperfusion injury. Biomed Pharmacother. 2019;120:109464.
   PubMed Web of Science ®Google Scholar
• Sanz MN, Grimbert L, Moulin M, et al. Inducible cardiac-specific deletion of Sirt1 in male mice reveals progressive cardiac dysfunction and sensitization of the heart to pressure overload. IJMS. 2019;20(20):5005.
   Google Scholar
• Tao A, Xu X, Kvietys P, et al. Experimental diabetes mellitus exacerbates ischemia/reperfusion-induced myocardial injury by promoting mitochondrial fission: Role of down-regulation of myocardial Sirt1 and subsequent akt/Drp1 interaction. Int J Biochem Cell Biol. 2018;105:94–103.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.
   PubMedGoogle Scholar
• Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol. 2019;317(4):F767–F780.
   PubMed Web of Science ®Google Scholar
• Adingupu DD, Gopel SO, Gronros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice. Cardiovasc Diabetol. 2019;18(1):16.
   PubMedGoogle Scholar
• Takasu T, Takakura S. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sci. 2019;230:19–27.
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693–1702.
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–255.
   PubMed Web of Science ®Google Scholar
• Lim A. Diabetic nephropathy – complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–381.
   PubMedGoogle Scholar
• Fioretto P, Zambon A, Rossato M, et al. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–S171.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: Effects and mechanisms. Diabetes Metab Syndr. 2018;12(6):1117–1123.
   PubMed Web of Science ®Google Scholar
• Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: Insights from the CREDENCE trial. Circulation. 2021;143(18):1735–1749.
   PubMed Web of Science ®Google Scholar
• Kario K, Okada K, Kato M, et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, Placebo-Controlled SACRA study. Circulation. 2019;139(18):2089–2097.
   Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Dia Care. 2015;38(3):420–428.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Izzo JL, Lee J, et al. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation. 2019;139(18):2098–2109.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia A, Simental-Mendia M, Millan-Alanis JM, et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and Meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068.
   PubMed Web of Science ®Google Scholar
• Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.
   PubMed Web of Science ®Google Scholar
• Basu D, Huggins LA, Scerbo D, et al. Mechanism of increased ldl (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207–2216.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8.
   PubMed Web of Science ®Google Scholar
• Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630–1641.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Summary of revisions: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S4–S6.
   PubMedGoogle Scholar
• McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):531–546.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98(4):839–848.
   PubMed Web of Science ®Google Scholar